Raritan Pharmaceuticals
Raritan Pharmaceuticals, a prominent player in the pharmaceutical industry, is headquartered in the United States and operates across various regions. Founded in 2007, the company has established itself as a leader in developing innovative therapies, particularly in the fields of oncology and infectious diseases. Raritan Pharmaceuticals is renowned for its unique approach to drug formulation and delivery, focusing on enhancing patient outcomes through advanced technology. The company’s core products include a range of specialty pharmaceuticals that address unmet medical needs, setting them apart in a competitive market. With a commitment to quality and efficacy, Raritan has achieved significant milestones, including strategic partnerships and successful product launches, solidifying its position as a trusted name in the pharmaceutical landscape.
DitchCarbon Score
How does Raritan Pharmaceuticals's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Raritan Pharmaceuticals's score of 3 is lower than 85% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Raritan Pharmaceuticals's reported carbon emissions
Raritan Pharmaceuticals, headquartered in the US, currently does not have publicly available carbon emissions data for the most recent year, nor do they have specified reduction targets or initiatives outlined in their climate commitments. Without specific emissions figures or reduction strategies, it is challenging to assess their current environmental impact or future commitments in relation to carbon emissions. As the pharmaceutical industry increasingly focuses on sustainability, Raritan Pharmaceuticals may need to establish clear climate goals and reporting practices to align with industry standards and expectations.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Raritan Pharmaceuticals is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
